Newest FDA-ap­proved opi­oid use dis­or­der drug en­ters the mar­ket with flex­i­ble dos­ing

The newest ap­proved opi­oid use dis­or­der drug is lean­ing on its flex­i­ble dos­ing sched­ule and in­jec­tion site con­ve­nience to gain trac­tion. Brae­burn’s Brixa­di can be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER